aboutnav prodnav sciandpubnav newsnavroll investorsnavroll careersnav contactnav

Critical Therapeutics Receives Notice of Additional Deficiency From NASDAQ

Critical Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2008

Critical Therapeutics Files Registration Statement on Form S-4 with Securities and Exchange Commission

 
 
 
 

 


FORWARD-LOOKING STATEMENTS, click here.

Home | About | Products | Development Pipeline | News | Investors | Careers

© 2007 Critical Therapeutics, Inc. All rights reserved.
For ZYFLO® (zileuton tablets) prescribing information,
click here.
For ZYFLO CR™ (zileuton) extended-release tablets, click here.
For Terms of Use and Disclaimer,
click here.
For Privacy Policy,
click here.
This site is intended for residents of the United States, Puerto Rico
and U.S. territories.